



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

WASHINGTON STATE UNIVERSITY EXTENDS METACORE LICENSES FROM GENEGO

St. Joseph, Michigan, September 19th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Washington State University Tri-cities has extended their license of MetaCore. MetaCore's new release 4.0 has unique features that give researchers a multi-level analysis of experimental data with respect to functional processes, diseases and consensus pathways in just one click.

“We have been loyal MetaCore users for quite some time now and we have been able to make significant progress in our projects supported by the Department of Energy's Low Dose Radiation Research Program. The software helped us to interpret proteomic data from irradiated cells and to identify pathways responsible for cytokine release following radiation exposure. Understanding these pathways is important for both radiation protection standards and effective use of radiation therapy to treat cancer,” said Dr. John Miller, Associate Professor, Washington State University Tri-Cities, and Emeritus staff member at Pacific Northwest National Labs. “We like the openness of MetaCore that allows us to understand our data in terms of biological processes, not just lists of identified proteins.” Dr. Miller focuses on biological and environmental research including radiation induced protein release.

“We are very pleased that an exemplary academic such as Professor Miller finds high value in MetaCore as a research tool” said Julie Bryant, Vice President of Business Development at GeneGo. “Academic scientists are a fast growing and invaluable customer base for GeneGo. We like working with academics because of the high quality of research and challenging yet constructive feedback. GeneGo is known as the innovator in functional analysis, and many of our development ideas come from academic collaborations and requests.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.0™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product,

MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc